title: SCAI statement on drug-eluting stents: practice and health care delivery implications.
authors.affiliation: Heart and Vascular Center, MetroHealth Medical Center, Cleveland, Ohio 44109, USA. jhodgson@metrohealth.org
authors.forename: John McB
authors.initials: JM
authors.lastname: Hodgson
authors.forename: Spencer B
authors.initials: SB
authors.lastname: King
authors.forename: Ted
authors.initials: T
authors.lastname: Feldman
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Cowley
authors.forename: Lloyd W
authors.initials: LW
authors.lastname: Klein
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Babb
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000592:standards; D003695:Delivery of Health Care / Q000592:standards*; D004333:Drug Administration Routes; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000592:standards*; D015607:Stents / Q000009:adverse effects / Q000592:standards*
chemical_list: D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents